Shanghai Pharmaceuticals Holding Co. Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic a… Read more
Shanghai Pharmaceuticals Holding Co. Ltd (SHPMF) - Net Assets
Latest net assets as of March 2025: $85.30 Billion USD
Based on the latest financial reports, Shanghai Pharmaceuticals Holding Co. Ltd (SHPMF) has net assets worth $85.30 Billion USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($225.87 Billion) and total liabilities ($140.57 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $85.30 Billion |
| % of Total Assets | 37.77% |
| Annual Growth Rate | 22.36% |
| 5-Year Change | 52.98% |
| 10-Year Change | 147.7% |
| Growth Volatility | 78.63 |
Shanghai Pharmaceuticals Holding Co. Ltd - Net Assets Trend (1994–2024)
This chart illustrates how Shanghai Pharmaceuticals Holding Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Pharmaceuticals Holding Co. Ltd (1994–2024)
The table below shows the annual net assets of Shanghai Pharmaceuticals Holding Co. Ltd from 1994 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $83.74 Billion | +4.25% |
| 2023-12-31 | $80.33 Billion | +2.98% |
| 2022-12-31 | $78.00 Billion | +32.06% |
| 2021-12-31 | $59.07 Billion | +7.90% |
| 2020-12-31 | $54.74 Billion | +10.84% |
| 2019-12-31 | $49.39 Billion | +6.36% |
| 2018-12-31 | $46.43 Billion | +17.03% |
| 2017-12-31 | $39.68 Billion | +7.71% |
| 2016-12-31 | $36.83 Billion | +8.95% |
| 2015-12-31 | $33.81 Billion | +8.71% |
| 2014-12-31 | $31.10 Billion | +7.23% |
| 2013-12-31 | $29.00 Billion | +4.69% |
| 2012-12-31 | $27.70 Billion | +6.62% |
| 2011-12-31 | $25.98 Billion | +118.62% |
| 2010-12-31 | $11.88 Billion | +411.72% |
| 2009-12-31 | $2.32 Billion | +11.13% |
| 2008-12-31 | $2.09 Billion | +6.71% |
| 2007-12-31 | $1.96 Billion | -5.26% |
| 2006-12-31 | $2.07 Billion | +3.04% |
| 2005-12-31 | $2.01 Billion | -2.68% |
| 2004-12-31 | $2.06 Billion | -3.12% |
| 2003-12-31 | $2.13 Billion | +6.39% |
| 2002-12-31 | $2.00 Billion | +9.98% |
| 2001-12-31 | $1.82 Billion | +84.53% |
| 2000-12-31 | $985.30 Million | +15.93% |
| 1999-12-31 | $849.92 Million | +19.13% |
| 1998-12-31 | $713.42 Million | +149.80% |
| 1997-12-31 | $285.60 Million | +51.01% |
| 1996-12-31 | $189.12 Million | +3.37% |
| 1995-12-31 | $182.95 Million | -6.94% |
| 1994-12-31 | $196.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Pharmaceuticals Holding Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 221667.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $36.55 Billion | 50.99% |
| Common Stock | $3.71 Billion | 5.17% |
| Other Components | $31.42 Billion | 43.84% |
| Total Equity | $71.68 Billion | 100.00% |
Shanghai Pharmaceuticals Holding Co. Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Pharmaceuticals Holding Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bestechnic (Shanghai) Co. Ltd. A
SHG:688608
|
$2.47 Billion |
|
STRIDE INC. DL -0001
F:0AJ
|
$2.47 Billion |
|
MAG Silver Corp
NYSE MKT:MAG
|
$2.47 Billion |
|
Derwent London PLC
PINK:DWVYF
|
$2.47 Billion |
|
Bel Fuse B Inc
NASDAQ:BELFB
|
$2.47 Billion |
|
Alliance Resource Partners LP
NASDAQ:ARLP
|
$2.47 Billion |
|
RED ROCK RESORTS A DL-01
F:RRK
|
$2.47 Billion |
|
Mineral Resources Limited
PINK:MALRF
|
$2.47 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Pharmaceuticals Holding Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 68,524,143,051 to 71,675,619,971, a change of 3,151,476,920 (4.6%).
- Net income of 4,552,528,438 contributed positively to equity growth.
- Dividend payments of 3,603,675,705 reduced retained earnings.
- Other comprehensive income decreased equity by 1,532,104,583.
- Other factors increased equity by 3,734,728,770.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.55 Billion | +6.35% |
| Dividends Paid | $3.60 Billion | -5.03% |
| Other Comprehensive Income | $-1.53 Billion | -2.14% |
| Other Changes | $3.73 Billion | +5.21% |
| Total Change | $- | 4.60% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Pharmaceuticals Holding Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.87x to 0.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $0.40 | $1.56 | x |
| 1995-12-31 | $0.38 | $1.56 | x |
| 1996-12-31 | $0.39 | $1.56 | x |
| 1997-12-31 | $0.59 | $1.56 | x |
| 1998-12-31 | $1.23 | $1.56 | x |
| 1999-12-31 | $1.29 | $1.56 | x |
| 2000-12-31 | $1.63 | $1.56 | x |
| 2001-12-31 | $3.09 | $1.56 | x |
| 2002-12-31 | $3.20 | $1.56 | x |
| 2003-12-31 | $3.55 | $1.56 | x |
| 2004-12-31 | $3.62 | $1.56 | x |
| 2005-12-31 | $3.61 | $1.56 | x |
| 2006-12-31 | $3.60 | $1.56 | x |
| 2007-12-31 | $2.87 | $1.56 | x |
| 2008-12-31 | $2.97 | $1.56 | x |
| 2009-12-31 | $0.92 | $1.56 | x |
| 2010-12-31 | $4.58 | $1.56 | x |
| 2011-12-31 | $9.53 | $1.56 | x |
| 2012-12-31 | $9.16 | $1.56 | x |
| 2013-12-31 | $9.65 | $1.56 | x |
| 2014-12-31 | $10.35 | $1.56 | x |
| 2015-12-31 | $11.13 | $1.56 | x |
| 2016-12-31 | $11.76 | $1.56 | x |
| 2017-12-31 | $12.66 | $1.56 | x |
| 2018-12-31 | $13.77 | $1.56 | x |
| 2019-12-31 | $14.66 | $1.56 | x |
| 2020-12-31 | $15.96 | $1.56 | x |
| 2021-12-31 | $17.37 | $1.56 | x |
| 2022-12-31 | $19.26 | $1.56 | x |
| 2023-12-31 | $18.51 | $1.56 | x |
| 2024-12-31 | $19.35 | $1.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Pharmaceuticals Holding Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.35%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.65%
- • Asset Turnover: 1.24x
- • Equity Multiplier: 3.09x
- Recent ROE (6.35%) is below the historical average (9.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 10.48% | 8.54% | 0.57x | 2.15x | $940.26K |
| 1995 | 10.03% | 5.44% | 0.75x | 2.46x | $52.68K |
| 1996 | 8.04% | 4.74% | 0.64x | 2.65x | $-3.70 Million |
| 1997 | 10.04% | 8.44% | 0.57x | 2.07x | $126.97K |
| 1998 | 13.17% | 1.78% | 1.69x | 4.37x | $18.94 Million |
| 1999 | 15.04% | 2.08% | 1.48x | 4.87x | $31.65 Million |
| 2000 | 23.28% | 4.02% | 1.30x | 4.45x | $105.43 Million |
| 2001 | 9.65% | 2.79% | 1.21x | 2.85x | $-5.25 Million |
| 2002 | 8.07% | 1.74% | 1.34x | 3.46x | $-30.11 Million |
| 2003 | 8.93% | 1.58% | 1.59x | 3.56x | $-18.53 Million |
| 2004 | 5.28% | 0.86% | 1.67x | 3.67x | $-83.19 Million |
| 2005 | 2.87% | 0.47% | 1.68x | 3.63x | $-125.23 Million |
| 2006 | 3.91% | 0.60% | 1.71x | 3.80x | $-106.84 Million |
| 2007 | 4.04% | 0.48% | 1.95x | 4.34x | $-97.86 Million |
| 2008 | 4.85% | 0.50% | 2.13x | 4.59x | $-86.92 Million |
| 2009 | 9.45% | 0.89% | 2.26x | 4.72x | $-10.02 Million |
| 2010 | 14.98% | 3.66% | 1.33x | 3.08x | $454.80 Million |
| 2011 | 8.85% | 3.72% | 1.15x | 2.07x | $-265.61 Million |
| 2012 | 8.33% | 3.02% | 1.33x | 2.07x | $-411.06 Million |
| 2013 | 8.64% | 2.87% | 1.39x | 2.17x | $-352.46 Million |
| 2014 | 9.31% | 2.80% | 1.44x | 2.31x | $-191.08 Million |
| 2015 | 9.61% | 2.73% | 1.42x | 2.48x | $-116.04 Million |
| 2016 | 10.11% | 2.65% | 1.46x | 2.62x | $34.14 Million |
| 2017 | 10.35% | 2.69% | 1.39x | 2.77x | $117.56 Million |
| 2018 | 9.95% | 2.44% | 1.25x | 3.25x | $-20.29 Million |
| 2019 | 9.80% | 2.19% | 1.36x | 3.29x | $-84.91 Million |
| 2020 | 9.91% | 2.34% | 1.29x | 3.29x | $-39.25 Million |
| 2021 | 10.32% | 2.36% | 1.32x | 3.31x | $157.52 Million |
| 2022 | 8.38% | 2.42% | 1.17x | 2.95x | $-1.09 Billion |
| 2023 | 5.50% | 1.45% | 1.23x | 3.09x | $-3.08 Billion |
| 2024 | 6.35% | 1.65% | 1.24x | 3.09x | $-2.62 Billion |
Industry Comparison
This section compares Shanghai Pharmaceuticals Holding Co. Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,254,633,395
- Average return on equity (ROE) among peers: -3.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Pharmaceuticals Holding Co. Ltd (SHPMF) | $85.30 Billion | 10.48% | 1.65x | $2.47 Billion |
| Accendra Health Inc (ACH) | $314.40 Million | 8.91% | 1.75x | $22.90K |
| Arjo AB (publ) (ARRJF) | $6.88 Billion | 10.78% | 1.12x | $491.29 Million |
| Cardinal Health Inc (CAH) | $255.60 Million | 13.15% | 1.57x | $50.81 Billion |
| Cencora Inc. (COR) | $4.01 Billion | 11.02% | 2.01x | $62.31 Billion |
| Cosmos Health Inc. (COSM) | $36.04 Million | -51.45% | 0.83x | $8.90 Million |
| EDAP TMS SA (EDAP) | $50.05 Million | 1.40% | 0.54x | $115.72 Million |
| Empro Group Inc. Ordinary shares (EMPG) | $741.21K | -42.90% | 4.10x | $9.16 Million |
| Energy Management International Inc (ENMI) | $-362.21K | 0.00% | 0.00x | $383.13K |
| Exlites Holdings International Inc (EXHI) | $-84.27 | 0.00% | 0.00x | $574.58K |
| Galenica AG (GALNF) | $999.54 Million | 12.50% | 1.21x | $3.75 Billion |